Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Clinical trial NCT06043713 · RECRUITING
Trial details
- NCT number
- NCT06043713
- Sponsor
- Fred Hutchinson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-15
- Primary completion
- 2028-01-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.